Antidepressants During Pregnancy and Lactation: Pharmacokinetics and Clinical Implications

July 27, 2015 updated by: Chantal Csajka, Centre Hospitalier Universitaire Vaudois

Antidepressant Treatments During Pregnancy and Lactation: Prediction of Drug Exposure Through Breastfeeding and Evaluation of Drug Effect on the Neonatal Adaptation and the Development of the Young Child

Background: The childbearing years are a time of increased vulnerability to the onset of mood disorders in women and a high prevalence of exposure to antidepressant drugs during pregnancy and postpartum has been reported. However, the lack of information regarding the milk transfer and the safety of these drugs in breastfed infants and the related fear of adverse events for the sucking infant are some of the factors responsible for stopping prematurely breast-feeding or avoiding drug therapy. Selective serotonin reuptake inhibitors (SSRI) and selective serotonin and noradrenaline reuptake inhibitors (SNRI) are the most frequently prescribed antidepressant drugs during pregnancy and the post-partum period. They exhibit a wide interpatient variability in their concentration profiles that has been related to numerous environmental, stereochemical, demographic and genetic influences that might alter the level of exposure of breastfed newborns. Limited information is available regarding the safety of use of these antidepressant drugs during lactation, and is generally derived from small studies. A comprehensive description of their distribution and quantification in milk in a larger cohort of patients under various influences and the resulting impact on milk concentrations is lacking.

Objectives: The current proposal addresses the primary objectives of quantifying the range of concentration to citalopram, escitalopram, sertraline, fluoxetine, paroxetine, fluvoxamine, duloxetine and venlafaxine in mother plasma and breast milk in relation to genetic polymorphisms, stereochemistry, demographics and environmental factors in a large cohort of depressive mothers. This will enable to derive the exposure to the breast-fed child taking into account this variability and therefore better adjust treatment to potential influences. As secondary objectives, we will examine the neurodevelopmental outcome of a sub-set of infants subjected to SSRI/SNRI in utero and/or during breastfeeding at birth, 6, 18 and 36 months, and compared to that of a control population of infants not subjected to this treatment.

Expected Results: The proposed strategy will offer new information regarding the expected level of drug exposure associated with each or with a combination of risk factors and help for optimizing the security and rationalizing the use of antidepressant treatment in lactating women. Hence, research on the safety of use of these drugs for the developing child is an area of great public health significance.

Study Overview

Status

Unknown

Conditions

Intervention / Treatment

Detailed Description

see brief summary

Study Type

Interventional

Enrollment (Anticipated)

500

Phase

  • Phase 4

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • France
    • Meurthe-et-Moselle
      • Nancy, Meurthe-et-Moselle, France
        • Recruiting
        • Service d'Obstétrique, Service de Néonatologie; Centre Hospitalier Universitaire Nancy
        • Contact:
        • Principal Investigator:
          • Jean-Michel Hascoët, Prof MD
        • Sub-Investigator:
          • Catherine Lamy, MD
    • Rhône
      • Lyon, Rhône, France
        • Recruiting
        • Service d'Obstétrique, Service de Néonatologie; Hospices civiles de Lyon (HCL)
        • Sub-Investigator:
          • Etienne BEAUFILS, MD
        • Contact:
        • Principal Investigator:
          • Olivier Claris, Prof MD
        • Sub-Investigator:
          • Pascal Gaucherand, Prof MD
        • Sub-Investigator:
          • Kim NGuyen, MD
  • Switzerland
      • Geneva, Switzerland
        • Recruiting
        • Service d'Obstétrique, Service du Développement et de la Croissance; Hopitaux Universitaires Genevois (HUG)
        • Contact:
        • Principal Investigator:
          • Manuella Epiney, MD
        • Principal Investigator:
          • Cristina Borradori Tolsa, MD
    • Vaud
      • Lausanne, Vaud, Switzerland
        • Recruiting
        • Division de Pharmacologie Clinique, Service d'Obstétrique, Service de Néonatologie, Service de Pédopsychiatrie de liaison, Unité de Pharmacogénétique et Psychopharmacologie Clinique; Centre Hospitalier Universitaire Vaudois (CHUV)
        • Sub-Investigator:
          • Chin B Eap, Prof PhD
        • Contact:
        • Principal Investigator:
          • Chantal Csajka, Prof PhD
        • Sub-Investigator:
          • Alice Panchaud, PhD
        • Sub-Investigator:
          • Jean-Francois Tolsa, Prof MD
        • Sub-Investigator:
          • Yvan Vial, MD MER
        • Sub-Investigator:
          • Myriam Bickle Graz, MD
        • Sub-Investigator:
          • Mathilde Morisod Harari, MD
        • Sub-Investigator:
          • Céline Fischer, MD
      • Morges, Vaud, Switzerland
        • Recruiting
        • Service d'Obstétrique, Service de Pédiatrie; Ensemble Hospitalier de la Côte (EHC)
        • Contact:
        • Principal Investigator:
          • Sylvie Rouiller, MD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  • Patients planning to deliver in the 5 maternities involved in the study;
  • Mothers under treatment by any SSRI/SNRI (fluvoxamine, fluoxetine, paroxetine, duloxetine, citalopram, escitalopram, sertraline or venlafaxine);
  • Mothers who intent to breastfeed their child;
  • Ability to understand and willingness to sign a written informed consent document for plasma and milk withdrawal and pharmacogenetic testing.
  • For the neurodevelopment follow-up part,all babies of the Maternity of Lausanne, Morges or Geneva exposed to SSRI/SNRI will be enrolled. A control group of infants of the same socio-economic status as the subset of exposed patients will be recruited in the Maternity Hospital of Lausanne.

Exclusion Criteria:

  • Mothers <18 years of age patients;
  • Infants of gestational age < 34 weeks;
  • Mothers giving birth to infants with major malformations;
  • Inability to communicate due to language problems for the mother;
  • Patients with a socio-economic context making close monitoring of the child by the mother or a relative not possible.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
No Intervention: Control
Pregnant and/or nursing mothers not taking a SSRI or SNRI antidepressant are recruited in a non-exposed group (Control or no SSRI/SNRI). Control group participates only in the sub-studies related to neonatal adaptation, neurodevelopment, growth and early mother-infant relationship.
Experimental: SSRI/SNRI exposure
Pregnant and/or nursing mothers under SSRI or SNRI treatment are recruited in an exposed group (SSRI/SNRI exposure). Drug regimen including dosage, frequency and duration is not modified by the study.
Drug: SSRI/SNRI
Exposed group of mothers taking one of the mentioned antidepressant drugs of the class of selective serotonin reuptake inhibitors (SSRI) or serotonin/noradrenalin reuptake inhibitors (SNRI).
Other Names:
  • fluoxetine
  • duloxetine
  • escitalopram
  • fluvoxamine
  • paroxetine
  • sertraline
  • venlafaxine
  • citalopram

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Evaluate the pharmacokinetics of SSRI/SNRI antidepressant drugs in breast milk secretion
Time Frame: week 1 and week 4-6 postpartum

The principal aim is to derive exposure to the breast-fed child by simulation while integrating influencing factors on pharmacokinetics (as genetic polymorphism, stereochemistry, demographics or environmental aspects).

5ml blood, 10ml fore-milk and 10ml hind-milk are taken from the mother during the same feed at week 1 and week 4-6 postpartum. Antidepressant drug concentrations are determined by LC-MS/MS and milk composition by human milk analyzer.Pharmacogenetic tests are performed with PCR-Taqman on maternal blood samples and cover genes involved in the metabolism (e.g CYP) and distribution (e.g. p-Gp) of antidepressants. Simulation of antidepressant drug secretion into breast milk will take into account all this information and will be performed with non-linear mixed effects modelling techniques.
week 1 and week 4-6 postpartum

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Examine neonatal adaptation
Time Frame: delivery and week 1 postpartum

The specific aim is to evaluate neonatal adaptation after in utero exposure to antidepressants and its relation to cord blood concentration.

5ml blood are taken from the umbilical cord and the mother at delivery. Antidepressant drug concentrations are determined by LC-MS/MS. Finnegan Score is used to evaluate the severity of possible withdrawal or discontinuation syndrome in exposed newborns.
delivery and week 1 postpartum
Examine neurodevelopment
Time Frame: week 1, month 6, 18 and 36 postpartum

The specific aim is to evaluate neurodevelopment of a sub-set of infants exposed to any SSRI/SNRI in utero and/or during breastfeeding compared to a control population of infants not exposed to this treatment.

During week 1 postpartum, somatic and neurologic state of the newborn are evaluated by a pediatrician using routine measures as well as specific tools (Dubowitz's neurologic assessment, Prechtl's general movements). At month 6,18 and 36, neurodevelopment of the infants are assessed using Hammersmith Infant Neurological Examination and Bayley Scales of Infant Development III. At the same time, mother's mental well-being is determined by using self-administered questionnaires (Edinburgh Postnatal Depression Scale, State-Trait Anxiety Inventory, Parental Sens of Competence and Revised Infant Temperament Questionnaire).
week 1, month 6, 18 and 36 postpartum
Study of growth
Time Frame: birth, month 6, 18 and 36 postpartum

The specific aim is to evaluate growth of infants exposed to any of the SSRI/SNRI commercialized, compared to standardized growth charts.

Usual infant growth information (size, body weight, head circumference) are collected routinely at birth and month 6,18,36.
birth, month 6, 18 and 36 postpartum
Examine early mother-infant relationship
Time Frame: Month 6 postpartum

The specific aim is to explore the quality of early mother-infant relationship of a sub-set of infants whose mothers are treated with SSRI/SNRI, compared to that of a control population of infants not exposed to this treatment.

At month 6 postpartum, mother-infant relationship is evaluated by pedopsychiatrists using Care Index.
Month 6 postpartum

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Centre Hospitalier Universitaire Vaudois

Collaborators

Hospices Civils de Lyon
University Hospital, Geneva
Central Hospital, Nancy, France

Investigators

  • Principal Investigator: Chantal Csajka, Prof PhD, Centre Hospitalier Universitaire Vaudois (CHUV)

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

August 1, 2012

Primary Completion (Anticipated)

December 1, 2016

Study Completion (Anticipated)

December 1, 2018

Study Registration Dates

First Submitted

February 4, 2013

First Submitted That Met QC Criteria

February 20, 2013

First Posted (Estimate)

February 21, 2013

Study Record Updates

Last Update Posted (Estimate)

July 28, 2015

Last Update Submitted That Met QC Criteria

July 27, 2015

Last Verified

July 1, 2015

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • SSRI-Milk
  • 320030_135650 (Other Grant/Funding Number: Swiss National Science Foundation (SNSF))
  • 2012-004509-29 (EudraCT Number)

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Depressive Disorder

Clinical Trials on SSRI/SNRI

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Pakistan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe